SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue reaching $11.1 million, a 116.8% increase year over year. The growth was primarily driven by higher installations of its SSi Mantra surgical robotic system and increased procedure volumes. The company's installed base expanded to 194 SSi Mantra systems across 11 countries, with nearly 9,750 cumulative robotic procedures completed as of the end of the quarter.
The company secured regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines during the quarter, broadening its international market access. Additionally, SS Innovations recently completed the world's longest-distance robotic cardiac telesurgery, showcasing the capabilities of its remote surgery platform. As of June 22, 2026, the cumulative number of multi-specialty procedures performed with the SSi Mantra system totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used for over 170 different types of procedures.
The company continues to pursue regulatory clearance in both the United States and Europe while expanding its presence in emerging healthcare markets. SS Innovations is a developer of innovative surgical robotic technologies for cardiac and other surgeries, including telesurgeries. For more information, visit the company's website at www.SSInnovations.com.
This announcement underscores the accelerating adoption of surgical robotics globally and the potential for telesurgery to expand access to specialized surgical care. The company's strong financial performance and international expansion signal growing confidence in its technology. The achievement of the world's longest-distance robotic cardiac telesurgery highlights the platform's reliability and potential to bridge healthcare gaps in remote areas.
As SS Innovations pursues approvals in the U.S. and Europe, its success in emerging markets may serve as a springboard for broader market penetration. The company's focus on training physicians and expanding its procedure repertoire suggests a strategic approach to building a sustainable ecosystem around its technology.
